nimacimab
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2019 (NCT03900325)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cannabinoid receptorINHIBITOR
Cannabinoid receptor inhibitor
- Cannabinoid CB1 receptorNEGATIVE ALLOSTERIC MODULATOR
Cannabinoid CB1 receptor negative allosteric modulator
Stabilizes the inactive conformation of CB1.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298095 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06577090 | Phase 2 | Aug 22, 2024 | SkyePharma AG |
| NCT03900325 | Phase 2 | May 31, 2019 | Bird Rock Bio, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bird Rock Bio, Inc. | For profit | 1 | 1 | 1 | 2019 |
| SkyePharma AG | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1